Inhibition

Inhibition is a broad term for any process in which a molecule reduces or blocks the normal activity of a protein — most commonly an enzyme, a receptor, or a transporter. It is the pharmacological opposite of activation: where an activating molecule switches something on or amplifies it, an inhibitor turns it down or off.

Almost every drug class includes inhibitors of one kind or another. Understanding inhibition helps explain why substances slow the breakdown of certain chemicals, block the effects of others, and why combining drugs can cause one to linger far longer or more powerfully than expected.

How it works · its role

The most important distinction is between competitive and non-competitive inhibition. A competitive inhibitor occupies the same binding site as the molecule the protein normally acts on; the natural molecule can still displace it if present in high enough concentration. A non-competitive inhibitor binds elsewhere on the protein, changing its shape in a way that impairs function — and cannot be overcome simply by adding more of the natural molecule.

A second distinction is reversibility. Most therapeutic inhibitors bind temporarily and eventually dissociate, restoring normal protein function. Irreversible inhibitors form a permanent bond; activity returns only as the body synthesises fresh protein. Irreversible inhibition produces effects that persist for days or weeks, which has significant implications for drug interactions and washout periods.

Relevance to substances & effects

Inhibition underpins several of the most widely used drug classes. SSRIs inhibit the SERT, slowing the reuptake of serotonin and raising its effective concentration. Monoamine oxidase inhibitors (MAOIs) block the enzyme that degrades dopamine, serotonin, and norepinephrine. Opioid antagonists such as naloxone occupy opioid receptors without activating them, blocking and reversing the drugs they displace.

Enzyme inhibition also shapes how the body handles other substances. Several compounds inhibit the CYP family of liver enzymes responsible for metabolising many drugs; when that clearance pathway is blocked, co-administered substances accumulate in the bloodstream. This is why certain combinations produce effects far stronger or longer-lasting than either drug would alone.

The distinction between reversible and irreversible inhibition carries direct harm-reduction weight. Irreversible MAOIs, for instance, leave the body unable to break down tyramine or co-administered serotonergic compounds for up to two weeks after the last dose — interaction risks do not end when the drug feels gone.